The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Chevallard Daniel R. since 2017.
This trader's CIK number is 1706176.
At the time of last reporting, Chevallard Daniel R. was the Chief Financial Officer of Lenz Therapeutics, Inc.. (stock ticker symbol LENZ).
Also see all insider trading activities at Lenz Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | LENZ | 3,188 | $49,987 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | VIRX | 0 | $0 | 3,405 | $2,492 | 6,889 | $0 |
| 2023 | VIRX | 0 | $0 | 10,867 | $12,113 | 20,666 | $0 |
| 2022 | VIRX | 0 | $0 | 14,781 | $42,234 | 27,556 | $0 |
| 2021 | VIRX | 0 | $0 | 7,579 | $36,464 | 23,777 | $9,000 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | RGLS | 0 | $0 | 15,922 | $20,782 | 0 | $0 |
| 2017 | RGLS | 54,945 | $49,999 | 0 | $0 | 0 | $0 |
1. Lenz Therapeutics, Inc. (LENZ)
2. Viracta Therapeutics, Inc. (VIRX)
3. Regulus Therapeutics Inc. (RGLS)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-05-14 | LENZ | Buy | 3,188 | 15.68 | 49,987 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-02-27 | VIRX | Sale | 3,405 | .73 | 2,492 |
| 2024-02-25 | VIRX | Option Ex | 6,889 | .00 | 0 |
| 2023-11-25 | VIRX | Option Ex | 6,889 | .00 | 0 |
| 2023-11-28 | VIRX | Sale | 3,720 | .50 | 1,860 |
| 2023-08-25 | VIRX | Option Ex | 6,888 | .00 | 0 |
| 2023-08-28 | VIRX | Sale | 3,512 | 1.45 | 5,092 |
| 2023-05-25 | VIRX | Option Ex | 6,889 | .00 | 0 |
| 2023-05-25 | VIRX | Sale | 3,635 | 1.42 | 5,161 |
| 2022-11-28 | VIRX | Sale | 3,532 | 2.72 | 9,607 |
| 2022-11-25 | VIRX | Option Ex | 6,889 | .00 | 0 |
| 2022-08-25 | VIRX | Option Ex | 6,889 | .00 | 0 |
| 2022-08-26 | VIRX | Sale | 3,655 | 4.02 | 14,678 |
| 2022-05-25 | VIRX | Option Ex | 6,889 | .00 | 0 |
| 2022-05-26 | VIRX | Sale | 3,596 | 1.90 | 6,835 |
| 2022-02-25 | VIRX | Option Ex | 6,889 | .00 | 0 |
| 2022-02-28 | VIRX | Sale | 3,998 | 2.78 | 11,114 |
| 2021-11-25 | VIRX | Option Ex | 13,777 | .00 | 0 |
| 2021-11-29 | VIRX | Sale | 4,325 | 4.82 | 20,842 |
| 2021-11-26 | VIRX | Sale | 3,254 | 4.80 | 15,622 |
| 2021-09-28 | VIRX | Option Ex | 10,000 | .90 | 9,000 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-07-01 | RGLS | Sale | 2,669 | 1.31 | 3,501 |
| 2019-05-15 | RGLS | Sale | 10,000 | 1.41 | 14,090 |
| 2019-04-01 | RGLS | Sale | 3,253 | .98 | 3,191 |
| 2017-07-25 | RGLS | Buy | 54,945 | .91 | 49,999 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Chevallard Daniel R. (Chief Financial Officer of Lenz Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.